Patent US4297347A successfully refreshed from Google Patents.
US4297347A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Nucleoside derivatives and an antileukemial agent containing the same as an active ingredient
Assignee: Individual
•
Filing: 1979-10-31
•
Granted: 1981-10-27
•
Expires: 1999-10-31
Abstract
Abstract A 3'-polyphosphate of pyrimidine nucleoside or guanosine or a pharmaceutically acceptable salt thereof which has high antileukemial activity and is low in toxicity is disclosed.
Inventors
- 👤 Nobuhiko Katsunuma
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 18:19
CPC Classifications
C; C07; C07H; C07H19/00; C07H19/02; C07H19/04; C07H19/06; C07H19/10; C07H19/16; C07H19/20
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
20 words
A compound selected from the group consisting of guanosine-3'-diphosphate, guanosine-3'-triphosphate, uridine-3'-diphosphate, uridine-3'-triphosphate, cytidine-3'-diphosphate, cytidine-3'-triphosphate, and a pharmaceutically acceptable salt thereof.
Claim 2
Dependent Claim
20 words
A compound selected from the group consisting of guanosine-3'-diphosphate, guanosine-3'-triphosphate, uridine-3'-diphosphate, uridine-3'-triphosphate, cytidine-3'-diphosphate, cytidine-3'-triphosphate, and a pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim
11 words
Guanosine-3'-diphosphate or a pharmaceutically acceptable salt thereof according to claim 1.
Claim 4
Dependent Claim
11 words
Guanosine-3'-triphosphate or a pharmaceutically acceptable salt thereof according to claim 1.
Claim 5
Dependent Claim
11 words
Uridine-3'-diphosphate or a pharmaceutically acceptable salt thereof according to claim 1.
Claim 6
Dependent Claim
11 words
Uridine-3'-triphosphate or a pharmaceutically acceptable salt thereof according to claim 1.
Claim 7
Dependent Claim
11 words
Cytidine-3'-diphosphate or a pharmaceutically acceptable salt thereof according to claim 1.
Claim 8
Dependent Claim
11 words
Cytidine-3'-triphosphate or a pharmaceutically acceptable salt thereof according to claim 1.
Claim 9
Dependent Claim
27 words
An agent effective against L5178Y lymphatic leukemia in mice containing a pharmaceutically acceptable carrier and a pharmaceutically acceptable amount of a compound in accordance with claim 1.
References Cited (Backward Citations)
US3382233A
Cited
US3299042A
Cited
US3475409A
Cited
US3462416A
Cited
US3830798A
Cited
US4141972A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-10-26 | 1985-04-27 | 1985-10-27 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-10-26 | 1989-04-27 | 1989-10-27 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-10-26 | 1993-04-27 | 1993-10-27 | $7700.00 | Window Closed / Lapsed |